254 Results
Biodesix Study Shows Proprietary Device Collects, Separates, and Transports Blood at Ambient Temperature. Findings Suggest Blood Collection Device Simplifies Specimen Collection and Transport While Maintaining Accuracy of Diagnostic Test Results
Data presented at the American College of Chest Physicians (CHEST) annual meeting, demonstrate the value of the Nodify Lung™ testing strategy and confirm previously reported performance of the Nodify XL2® and Nodify CDT™ tests.
Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company expects to report record fourth quarter 2020 preliminary unaudited revenue in a range of $25 million to $27 million.
Biodesix, Inc. (Nasdaq: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced publication of an analysis of the company’s Nodify XL2® lung nodule test.
Biodesix Announces Hiring of Ryan Siurek as Chief Accounting Officer.
HiberCell today announced an agreement with Biodesix, Inc. to further the development of an enzyme-linked immunosorbent assay (ELISA) as a companion diagnostic in future registrational trials in breast cancer for Imprime PGG programs.
Purdue University is partnering with a Colorado company led by a Purdue alum to offer rapid antigen COVID-19 testing for undergraduate, graduate and professional students taking classes on the West Lafayette campus who will be living off campus (not in the residence halls or in Fraternity, Sorority and Cooperative Life housing) during the spring 2021 semester.
Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, today announced financial and operating results for the third quarter ended September 30, 2020 and provided a corporate update.
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, is proud to announce the launch and active recruitment of a firstin-class biomarker study aligned with the recommendations from the official 2018 American Thoracic Society (ATS) policy statement on the early detection of lung cancer.
Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix”) today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share.